Alphatec Holdings Inc. (NASDAQ:ATEC) is one of the best high short interest stocks with biggest upside potential. On January 27, TD Cowen lowered its price target for Alphatec to $20 from $27 while maintaining a Buy rating following a transfer of coverage. The firm suggested that the current market expectations do not fully appreciate the company’s growth vectors, such as its recent 2026 revenue outlook of $890 million and the acquisition of exclusive US rights to Theradaptive’s OsteoAdapt bone graft. The ...

Core Viewpoint - Alphatec (ATEC) shares experienced a significant increase of 9.5% to close at $17.46, driven by strong trading volume and investor optimism regarding its preliminary financial results for 2025 and strategic acquisitions [1][2]. Financial Performance - For 2026, Alphatec projects total revenue of $890 million, indicating a growth of approximately 17% compared to the full year 2025 [2]. - The company is expected to report quarterly earnings of $0.04 per share, reflecting a year-over-year increase of 117.4% [3]. - Revenues for the upcoming quarter are anticipated to be $212.6 million, which is a 20.3% increase from the same quarter last year [3]. Market Position and Trends - The consensus EPS estimate for Alphatec has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4]. - The stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [4]. - In the same medical instruments industry, Integer (ITGR) has also maintained a Zacks Rank of 3, with an EPS estimate of $1.7, representing an 18.9% increase from the previous year [5].

Core Insights - Alphatec Holdings, Inc. (NASDAQ:ATEC) is recognized as one of the top 14 booming stocks to consider for investment at present [1] Financial Performance - Preliminary total revenue for 2025 increased by 25%, expected to be between $763.4 million and $764.4 million, primarily driven by a 26% surge in surgical revenue [2] - The company reaffirmed its full-year guidance for adjusted EBITDA at $91 million and ended the year with a cash balance of $161 million [2] 2026 Outlook - For fiscal 2026, Alphatec projects revenue of $890 million, with 90% expected to be surgical-related [3] - Adjusted EBITDA is anticipated to be around $130 million, and free cash flow for the year is forecasted at approximately $20 million [3] Strategic Developments - On the same day, Alphatec announced a strategic agreement with Theradaptive, Inc. to acquire exclusive distribution rights in the U.S. for Theradaptive's rhBMP-2 solution, OsteoAdapt, enhancing its position in the procedural ecosystem [4] Market Sentiment - Wall Street has a bullish outlook on Alphatec, with a consensus Strong Buy rating and a one-year average share price target of $24.55, indicating an upside of nearly 40% as of January 12 [5]

Market Overview - The S&P 500 has shown significant gains, registering a 16% increase in 2025, following a 24% rise in 2023 and a 23% rise in 2024, totaling approximately 80% over the past three years, marking the strongest three-year performance since a 90% surge from 2019 to 2021 [1][2]. Economic Forecast - A Financial Times survey predicts a 10% gain in the S&P 500 for 2026, with all surveyed banks expecting the index to surpass 7,500 [2]. - Goldman Sachs anticipates a 12% rally in 2026, driven by earnings growth supported by a strong economy and Federal Reserve rate cuts [2][3]. Stock Valuation Insights - Ben Snider from Goldman Sachs highlights that double-digit profit growth and improved productivity from AI position the market for continued bullish trends, although high stock valuations could pose risks if earnings fall short [3][4]. Stock Selection Methodology - The article identifies U.S.-based stocks with market capitalizations of at least $2 billion that have increased by at least 20% over the past three months, further narrowing the list to those with a 50-day moving average above a 200-day moving average [6]. - The final selection includes 14 stocks with the highest average upside potential, based on data as of January 12, 2026, and includes hedge fund holdings as of Q3 2025 for additional investor interest insights [6][7]. Featured Stocks Alphatec Holdings, Inc. (NASDAQ: ATEC) - Projected revenue for 2026 is between $890 million, with 90% expected to be surgical-related, and adjusted EBITDA anticipated at around $130 million [10]. - The company reported a 25% increase in total revenue for 2025, driven by a 26% surge in surgical revenue, and ended the year with a cash balance of $161 million [9]. - Wall Street has a consensus Strong Buy rating with a one-year average share price target of $24.55, indicating an upside of nearly 40% [12]. Terns Pharmaceuticals, Inc. (NASDAQ: TERN) - The stock has surged over 300% in the past three months, with analysts projecting a further 42.31% upside based on a one-year average share price target of $53.75 [16]. - The company received a Buy rating from Truist Financial, with a price target raised to $56 following positive Phase 1 study results for its lead program targeting chronic myeloid leukemia [14][15]. - Mizuho Securities also reiterated an Outperform rating, indicating strong potential for TERN-701 as a leading treatment for CML [15].

Company Overview - Alphatec Holdings, Inc. is a U.S.-based medical technology company that specializes in innovative solutions for spinal surgery, focusing on proprietary platforms and expanding its portfolio to address complex spinal conditions [6]. Insider Trading Activity - Craig E. Hunsaker, EVP of People & Culture at Alphatec Holdings, executed an open-market sale of 32,584 shares valued at $679,050.56 on December 10, 2025, at a price of $20.84 per share [4][5]. - This sale represented 2.53% of Hunsaker's direct ownership at the time, which is slightly below his historical median of 2.79% for sell trades [3]. - The transaction size was significantly below Hunsaker's recent median sale of 60,876 shares, indicating a smaller-than-usual transaction [4][5]. Market Performance - Alphatec's stock has seen a remarkable 116% rise over the last year, outperforming the S&P 500's 15% total return and the 2.8% decline in the State Street SPDR Health Care Equipment ETF [8]. - Despite a solid preliminary report in January 2026, the stock experienced a nearly 22% drop in one day due to a disappointing mid-teens growth projection, and the company remains unprofitable [9]. Strategic Developments - Alphatec recently announced a partnership with Theradaptive, granting it exclusive U.S. rights to commercialize the OsteoAdapt spinal fusion technology, which is still in clinical trials. This partnership could lead to surgeon adoption and revenue growth if successful [9].